AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00KT2KGM7
76.73▼ 4.06 (-5.03%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
80.79
Day's Range
76.58 – 80.22
52-Week Range
35.20 – 84.06
Volume
570.6K
Avg Volume
550.2K
Share Statistics
Shares Outstanding
Employees
366
Exchange
XNAS
Listed
2018-05-24
Share count as of July 24, 2026

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA)
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Market Cap?
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Market Cap is $12.0B, based on as-reported figures from SEC (XBRL) filings.
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Enterprise Value?
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Enterprise Value is $11.4B, based on as-reported figures from SEC (XBRL) filings.
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Trailing P/E?
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Trailing P/E is 148.4×, based on as-reported figures from SEC (XBRL) filings.
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Price / Sales?
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Price / Sales is 14.2×, based on as-reported figures from SEC (XBRL) filings.
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's EV / Revenue?
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's EV / Revenue is 13.6×, based on as-reported figures from SEC (XBRL) filings.
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's EV / EBITDA?
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's EV / EBITDA is 133.9×, based on as-reported figures from SEC (XBRL) filings.
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Revenue (TTM)?
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Revenue (TTM) is $840.8M, based on as-reported figures from SEC (XBRL) filings.
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Net Income (TTM)?
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Net Income (TTM) is $80.7M, based on as-reported figures from SEC (XBRL) filings.
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's EBITDA?
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's EBITDA is $102.0M, based on as-reported figures from SEC (XBRL) filings.
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Diluted EPS (TTM)?
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Diluted EPS (TTM) is 0.52, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · KNSAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Revenue
YoY growth+55.4%+55.5%+65.0%+61.2%
Costs and operating expenses:
Cost of goods sold
Collaboration expenses
Research and development
Selling, general and administrative
Total operating expenses
Income from operations
% of revenue11.2%13.7%9.8%13.3%
Other income, net
Income before income taxes
Provision for income taxes
Net income
% of revenue10.4%10.5%7.0%10.2%
Net income per share attributable to ordinary shareholders, basic
Net income per share attributable to ordinary shareholders, diluted